H. Lundbeck A/S HLBBF
7.10 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
7.10 Day range 7.10
5.70 52-week range 7.29
- YTD
- +3.50%
- 1 year
- +3.65%
- Market cap
- 7.04B
- EPS (ttm)
- 0.61
- P/E ratio
- 11.64
- YTD return
- +3.50%
- 1-year return
- +3.65%
- Volume
- 100
- Avg volume
- 57
- Open
- 7.10
- Previous close
- 7.10
- Day's range
- 7.10 – 7.10
- 52-week range
- 5.70 – 7.29
- Earnings date
- Aug 19, 2026
2Y +0.35 (+5.19%)
Next earnings
Aug 19, 2026
Expected Aug 19, 2026. Consensus EPS estimate 0.1718.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 19, 2026 | Jun 30, 2026 | 0.1718 | — | — | — |
| May 12, 2026 | Mar 31, 2026 | 0.2164 | 0.2575 | +0.04 | +18.99% |
| Feb 3, 2026 | Dec 31, 2025 | 0.1136 | 0.00785 | -0.11 | -93.09% |
| Nov 11, 2025 | Sep 30, 2025 | 0.137 | 0.1743 | +0.04 | +27.23% |
| Aug 12, 2025 | Jun 30, 2025 | 0.1503 | 0.153 | 0.00 | +1.80% |
| May 14, 2025 | Mar 31, 2025 | 0.1297 | 0.1709 | +0.04 | +31.77% |
News
H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript 
H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript 
H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript 
H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript 
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal 
H. Lundbeck A/S (HLBBF) Q3 2025 Earnings Call Transcript 
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
Your note
Sign in to keep a note on HLBBF — it syncs with the Stock Master app.